You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Mallinckrodt
Dow
McKesson
Medtronic

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Patent: 8,211,879

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,211,879
Title:Cationic steroid antimicrobial compositions and methods of use
Abstract: The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).
Inventor(s): Savage; Paul B. (Mapleton, UT), Leung; Donald (Englewood, CO)
Assignee: Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO)
Application Number:12/876,993
Patent Claims:see list of patent claims

Details for Patent 8,211,879

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Octapharma Usa Inc OCTAGAM IMMUNE GLOBULIN (HUMAN) immune globulin SOLUTION 125062 1 2004-05-21   Start Trial Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 search
Hoffman-la Roche PEGASYS peginterferon alfa-2a SYRINGE 103964 002 2002-10-16   Start Trial Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a VIAL; SUBCUTANEOUS 103964 001 2002-10-16   Start Trial Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 RX search
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05   Start Trial Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 RX search
Emergent ACCRETROPIN somatropin INJECTABLE;INJECTION 021538 001 2008-01-23   Start Trial Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 DISCN search
Sandoz OMNITROPE somatropin INJECTABLE;INJECTION 021426 004 2006-05-30   Start Trial Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 RX Orphan search
Sandoz OMNITROPE somatropin INJECTABLE;INJECTION 021426 003 2006-05-30   Start Trial Brigham Young University (Provo, UT) National Jewish Medical and Research Center (Denver, CO) 2026-02-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Dow
Mallinckrodt
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.